Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Barcoding _-__-__-__-__-__ seen this before....
Ph3 data imminent.
R/s announcement was a share grab. R/s was known coming anyways.
Valuations still hasn't changed infact went higher.
That's for sure!
yeah, it's not just the OTC that will blind side you with a RS.
I mean, we've waited that much, might as well wait a couple of days more... Personally i'll wait till the first week of June (end of the ASCO conference), if not by then, i'm out with whatever i have left.
How long have we been waiting for Phase lll results ..? Might be in 2036..
Not if they release the results before then. Imo, there's a chance (not gonna bet on the % here) they do that in order to maximize the effect of the upcoming 1:60 r/s. But they could also not give a flying fart, and release the data in June or whenever, after the split, and long after the bears had their way with the stock.
Why ? This will tank until Thursday. R//S will probably take place at .10. No way out.
The amount of manipulation occurring in the L2 is astounding. It's disgusting
Thank God didn’t buy this garbage back never change big RS and big offering after. Free ATM
What a friggin bitch
Frankfurt Market is down -33.53% , expecting another drop once US market opens up. Stay safe everyone
Frankfurt market has best bid order in at .1098 EU , as I said before get ready for a huge correction today the markets are extremely pissed at the RS news. I will be waiting this could be pretty gnarly in the pre-market in our market.
WELL PEEPS...IDK HOW ITS GONNA GO THIS WEEK AND FURTHER ON BUT WANTED TO SAY GOOD LUCK AND PROSPERITY TO ALL!!
I see a big offering coming after R/S
I tried telling this board for a year and a half how Lisa worked and that she was a slim bucket with no regard for shareholders. I advised all of those who were here at that time to go look at the past 3 reverse splits not the size but that happened and what was said. You must go back in time to see the PRs that were released then to
Each time she would say “if we even need to do one” And they always have. What is so disheartening is If, as we all suspected, the Phase III is positive results and they put out additional information to go along with the positive results why do it at all.
Put out distribution information, put out partner information, put out revenue projections. All of that puts the stock at $5 minimum and if you doubt that you don’t know Jack shit about bio tech drugs. Also with those thing and a pretty much a guaranteed FDA approval after positive results this RS is for the benefit of Lisa and her butt buddies.
And don’t anyone dare say it’s for NASDAQ compliance, last month she PRed they gave her to early August for gaining a minimum BID of a dollar.
Read my posts since Jan of this year you will see she is a snake and always will be.
Correct, a smart short seller will stand down and let the r/split jack up the share price, and let expected PR help it.
THEN, with 9-12 months to go from the PR to a possible FDA decision day? And likely a dilution move to raise cash off
the elevated share price? Then hit it..
Course, their risk is that with the low share count, IF there is any positive surprises, they could get 'fried' trying to cover
into a rally.
I'm quoting myself here, since i can't edit my prev post and i've found an answer, if anyone cares:
WTF did this jail bird do??? LMAO
Tutes loading , expect to see $75.00+ share by year end.
Interesting the PR is dated yesterday but the split takes place next Thursday. Why not split on Monday? My GUESS is they are going to release a material PR, maybe Mon or Tues, likely Tues. Seems like a shakeout. Also I noticed the reason for the R/S is compliance and to get price up to attract more institutional buyers. Meme, favorable PR possibilities allows hopeful expectations. I have no info, just opinion.
There will be a nice bounce coming.
The r/split has caused an interesting situation:
-drop the share count to a ridiculous low number, around 5 Million shares, creates a set up for one hell of a jump on PR if the market likes it.
-BUT if they need cash, I suspect the next move will be for a secondary, ATM of something like at least 10-15 Million shares to raise cash
-the higher share price will make it possible for the institutionals to be interested in the shares. Said it before, we the 'little people' aren't going
to pull the share price up by our own actions, it requires the institutionals. (was hoping to see 50 cents before they did a r/split tho)
-and I am now wondering if they know WHEN and WHAT the PH 3 results are?? Or at least know that its going to be available for release and that
it will negate the effect of the r/split and prevent at least in the short term, the piling on of the short sellers..
This has gotten ugly and interesting. On one hand, I missed out on the hit last night, so I can at least observe.
Remember, the biggest thing in this market is, is their MARKET CAP unreasonable relative to the potential revenues. I use that as a guide
to whether or not I want the shares at the PRICE & SHARE COUNT its at.. Is their justification for a higher share price.. To be determined.
DISCLAIMER: At the moment, I have no idea what a REASONABLE MARKET CAP is for them. I was only trading the shares for what I could
get while trying to figure this out. Good luck. Own none at the moment. Undecided as to whether or not I will again.
Honestly from what I've been watching I would be extremely careful on Monday. Remember the international markets were all closed, but everyone has seen this dip and I'm sure A LOT of people are pissed the fuck off. The Frankfurt market still has a share price of .24 EU , there is going to be a massive correction and sell off before anything else happens. The one thing I don't understand is why put out PR after hours and leave only the US market open to get dumped. Something is definitely happening behind the scenes. Stay safe y'all, I feel bad for everyone who watched their portfolio take an instant -50% L , including my own.
ouch...they worked the sheeep here once again
I don’t think they will have to cover the shorts.
If anything they will short more on the 23rd.
The split new price could be about $8 a share.
The shorts will hit it again to try to get it below $2
Then they may think about covering
There should be about 4.88 million shares after the split.
That is about the amount of shares when i 1st bought shares maybe 7 million shares.
JAGX kept selling shares into the market diluting shares. They will do it all over again if history repeats.
If they do a RS won’t it shake out all the short positions after the split and with phase 3 PR should pop huge!!!! Especially with all the craze hot meme stocks???
FFIE saved the day…
How do you think it will fare next week, before the split? Drop some more? More selling, more buying? The r/s 1:60 is horrible for any stock, but this has a big catalyst coming. Honestly, i don't know what to do on monday.
This management team at JAGX has hurt alot of investors through the years
I just sold my last 10,000 shares @ .14 that i paid 67 cents for but because i loaded way up around 10 cents that i made a profit on JAGX to the point that these were free trading shares.
If there is one thing i do not like it is the brutal reverse split.
This stock is brutal to the shareholders
I wish everyone the best of luck here.
I know how you feel...been burned like that enough... but at least they have a big hopeful catalyst ahead...many times a company has absolutely nothing in the works when they split....but not the case with JAGX...I hope it ends well for all involved.
Oh, i'm sure that's the plan, i mean, there's no other explanation for it. It's just a massive headache atm...
You never know DanDosh they might just do that directly after the split...it might be a strategic move so institutions might take interest.
At least it's a nice price to buy right now, for those that still have $ left aside to gamble the PIII catalyst. I think it will bounce a bit back, till may 23, based on this logic. Right?! Or maybe it's just my stupid copium, that got me burned so many times. God dammit...
They want to make it attractive to investors.... They'll announce PIII results, positive, at ASCO, but first they needed a stock with a price that's more attractive. It's a shitty situation, i had hoped they wouldn't do this, but they did nonetheless.
I figured they would at least wait until July considering they had until August 13th 2024.
I'm so pissed right now to sell at loss this pos stock, but the only saving will still be those damn PIII results. FFS. I should have listened when people said this stock murders its stockholders...
Split won't happen until next Thursday May 23rd
Yeah they announced it on their website before filing it.
https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-inc-announces-reverse-stock-split
Apparently, your dream turned into a nightmare.
Followers
|
156
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
6589
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |